Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated VRTX released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548.
One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck).
Vertex said that within 48 hours of surgery, bunionectomy, and tummy tuck, patients who received the high dose of VX-548 experienced significantly less pain than patients who received a placebo.
Read Next: Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance.
Bunionectomy patients who received the mid-level dose experienced more pain than those on placebo. And patients who received the lowest dose saw some improvement over the placebo, although it was not statistically significant.
Vertex executives said they would push the drug into pivotal trials later this year.
The Company plans to advance VX-548 into pivotal development in 2H of 2022.
Price Action: VRTX shares are up 2.63% at $263.27 during the market session on the last check Thursday.